← Back to Clinical Trials
Recruiting NCT05407857

NCT05407857 Taiwan Geriatric Study for Dementia Risk Prevention and Cognitive Enhancement by Multi-modal Intervention

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05407857
Status Recruiting
Phase
Sponsor Taipei Medical University Shuang Ho Hospital
Condition Dementia
Study Type INTERVENTIONAL
Enrollment 380 participants
Start Date 2022-07-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
multi-modal non-pharmacological intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 380 participants in total. It began in 2022-07-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A 3-arm randomized controlled trial of multi-modal non-pharmacological Intervention for preventing the risk of dementia in Taiwanese geriatric people

Eligibility Criteria

Inclusion Criteria: 1. People over 60 without dementia 2. Agree to join the study and sign the consent form 3. The Modified Rankin Scale (MRS) scores between 0-1 points 4. Education level: elementary or higher education (6 years) or can read and write Chinese 5. Very early dementia screening scale (AD-8) \< 2, or more than 2 points but without dementia diagnoses after refer to a neurologist. 6. Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score: above 8; diagnosed with mild cognitive impairment (MCI) or subjective cognitive decline (SCD) in the past six months. Exclusion Criteria: 1. Have been diagnosed with any kind of dementia 2. Suspected dementia patients or others who are not suitable to participate in the research assessed by a doctor at the first visit 3. Diseases affecting the safety of various interventional activities (such as remaining life less than two years, symptomatic heart/cerebrovascular disease within 6 months, vascular reperfusion or reconstruction-related surgery within one year, etc., malignant tumor within one year) 4. Severe blindness, hearing or communication impairment, or other difficulty in cooperating or completing assessments and interventions (especially exercise) in the study 5. Severe mental illnesses, including major depression disorder, or major neuromusculoskeletal disorders that are not suitable to join the study. 6. Drug or alcohol abuse in the last year 7. Overlapping with other interventional trials at the same time which may affect the evaluation results.

Contact & Investigator

Central Contact

Yi-Chun Kuan, MD

✉ yckuang2@gmail.com

📞 +886-222490088

Principal Investigator

Yi-Chun Kuan, MD

PRINCIPAL INVESTIGATOR

Taipei Medical University Shuang Ho Hospital

Frequently Asked Questions

Who can join the NCT05407857 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, up to 90 Years, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05407857 currently recruiting?

Yes, NCT05407857 is actively recruiting participants. Contact the research team at yckuang2@gmail.com for enrollment information.

Where is the NCT05407857 trial being conducted?

This trial is being conducted at New Taipei City, Taiwan.

Who is sponsoring the NCT05407857 clinical trial?

NCT05407857 is sponsored by Taipei Medical University Shuang Ho Hospital. The principal investigator is Yi-Chun Kuan, MD at Taipei Medical University Shuang Ho Hospital. The trial plans to enroll 380 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology